What is the purpose of the study?
The pharmaceutical company UCB is exploring a new oral drug to slow the progression of Parkinson’s, specifically among those diagnosed within the last 2 years.
This is a large scale Phase 2a study to evaluate the efficacy (i.e. does it actually work?), safety, tolerability, and pharmacokinetics (how does the drug behave in the body?) of orally taken drug UCB0599.
Who do the researchers need?
- People diagnosed with Parkinson’s in the past 2 years who are between 40 and 75 years of age
- Who have not taken drug treatments for their Parkinson’s, although you would still be eligible if you have taken a drug for less than 1 month
- Who can travel to the Lind Centre at Derriford Hospital, Plymouth.
What is involved?
You will be asked to visit the Lind Centre 16 times over the space of 18 months, where you will be given either the active drug or a placebo drug. Three of these visits can instead take place at your home. The study will involve a variety of investigations at each visit, including an MRI scan if you have not had one in the past 6 months.
Agreed expenses for your participation in this research will be reimbursed.
You can register your interest in joining the orchestra here.